Announcement
18 Jun 2024
In June 2024, US BARDA provided approximately USD 24 million to GeoVax Inc for a Phase 2b clinical trial of their COVID-19 vaccine candidate GEO-CM04S1 under Project NextGen.
Source
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
Implementation date
18 Jun 2024
Revocation date:
No revocation date
On 18 June 2024, the Biomedical Advanced Research and Development Authority (BARDA) announced funding for GeoVax to support a Phase 2b clinical trial of their investigational COVID-19 vaccine, GEO-...
See all
This state act is not part of any Thread yet.